info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Yeast Infection Companies

Yeast infections, particularly those caused by the overgrowth of Candida species, can affect various parts of the body, with vaginal yeast infections being one of the most common. Antifungal medications are commonly used for the treatment of yeast infections. Several pharmaceutical companies and healthcare organizations may be involved in the production and development of medications for yeast infection treatment. 

Yeast infections Market

 


Latest Yeast Infection Companies Updates:


Scynexis Their long-awaited first-in-class antifungal Brexafemme (ibrefungerp) secured European Marketing Authorization for both vaginal and vulvovaginal candidiasis in July 2023. Following its US approval in June 2022, Brexafemme's European launch strengthens Scynexis' market position.


Cidara Therapeutics Announced positive top-line data from their ReSTORE Phase 3 trial in December 2023, showcasing the efficacy and safety of rezafungin as a first-line treatment for candidemia and invasive candidiasis. Potential FDA approval could significantly bolster their presence in the market.


Evotec Partnered with Evolutions Therapeutics to develop novel antifungal treatments for recurrent vulvovaginal candidiasis (RVVC). Their combined expertise aims to bring faster and more effective solutions to this challenging area.


Astellas Initiated Phase 2b clinical trials for their investigational oral antifungal ASP2897 for treating both acute and RVVC. This innovative compound holds promise for expanding treatment options and improving adherence.


Meda Pharma Launched their OTC vaginal microbiome restoration product, Canesten BioBalance, in Europe. This probiotic-based product offers a non-antifungal approach for restoring vaginal health and preventing recurrent yeast infections.


Viome Expanded their personalized microbiome testing and supplement service to include support for vaginal health and yeast infection prevention. This personalized approach tailors probiotics and other supplements to individual needs for improved efficacy.


List of Yeast Infection Key companies in the market:



  • Sanofi

  • Astellas Pharma Inc

  • Synmedic Laboratories

  • Astra Zeneca

  • Synmedic Laboratories

  • Allergan

  • Pfizer Inc

  • Brundavan Laboratories

  • Merck & Co., Inc

  • Corden Pharma


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.